|
Dec 13
|
Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics
|
|
Dec 10
|
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
|
|
Nov 30
|
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
|
|
Nov 29
|
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
|
|
Nov 4
|
IZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 Years
|
|
Oct 22
|
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
|
|
Oct 19
|
China Arrests Japanese Executive Despite Tokyo’s Appeals
|
|
Aug 25
|
Astellas Joins Record Bond Sales by Japan Inc. With M&A Debt
|
|
Aug 23
|
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
|
|
Aug 21
|
Medicare drug price negotiations unlikely to be derailed by lawsuits: UBS
|
|
Aug 21
|
New Strong Sell Stocks for August 21st
|